Exisulind in the treatment of prostate cancer

W. Scott Webster, Bradley C. Leibovich

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Prostate cancer represents the most common noncutaneous malignancy in men. With the widespread use of prostate-specific antigen screening, as many as one in six men in the USA will be diagnosed with prostate cancer. Significant healthcare resources are currently devoted to the treatment of this disease, specifically aimed at improving the side effects of successful treatment. Surgery or radiation therapy provides the best chance of cure from this disease. However, as many as 50% of patients treated with curative intent will develop a recurrence 10-15 years following treatment. Hormonal ablation via medical or surgical castration provides disease control, but is associated with significant hot flushes, loss of libido and impotence. Selective, apoptotic antineoplastic drugs, such as exisulind, may provide an alternative method to treating or preventing prostate cancer. This drug profile reviews the evidence for the use of exisulind in the treatment of prostate cancer.

Original languageEnglish (US)
Pages (from-to)957-962
Number of pages6
JournalExpert review of anticancer therapy
Issue number6
StatePublished - Dec 1 2005


  • Exisulind
  • Prostate cancer
  • Selective apoptotic antineoplastic drugs

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Exisulind in the treatment of prostate cancer'. Together they form a unique fingerprint.

Cite this